mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.
It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.
Cognition Therapeutics has reported phase 2 data with its Alzheimer's disease candidate, claiming the results show proof-of-concept for the drug, although the study missed its main endpoint
Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and invest
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste